Surrozen (NASDAQ:SRZN) Earns “Buy” Rating from HC Wainwright

Surrozen (NASDAQ:SRZN)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $36.00 target price on the stock, up from their prior target price of $32.00. HC Wainwright’s price objective would suggest a potential upside of 37.72% from the company’s current price. HC Wainwright also issued estimates for Surrozen’s FY2030 earnings at ($3.54) EPS.

Other equities research analysts also recently issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research report on Thursday, January 22nd. Cantor Fitzgerald started coverage on Surrozen in a research report on Thursday, February 19th. They issued an “overweight” rating and a $40.00 price objective for the company. Finally, Wall Street Zen raised Surrozen to a “sell” rating in a report on Friday, November 28th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $38.00.

Surrozen Price Performance

Shares of Surrozen stock opened at $26.14 on Tuesday. Surrozen has a fifty-two week low of $5.90 and a fifty-two week high of $29.59. The firm has a fifty day moving average price of $24.34 and a two-hundred day moving average price of $18.81. The company has a market cap of $224.02 million, a PE ratio of -0.78 and a beta of 0.53.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($7.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.29) by ($6.30). The company had revenue of $0.53 million for the quarter, compared to the consensus estimate of $0.66 million. Surrozen had a negative return on equity of 1,240.42% and a negative net margin of 7,476.67%. Analysts expect that Surrozen will post -8.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Surrozen news, major shareholder Tcg Crossover Gp Ii, Llc purchased 106,658 shares of the business’s stock in a transaction on Tuesday, March 24th. The stock was purchased at an average price of $24.69 per share, for a total transaction of $2,633,386.02. Following the completion of the purchase, the insider directly owned 736,554 shares in the company, valued at approximately $18,185,518.26. This trade represents a 16.93% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Group Gp Lp Column III acquired 18,052 shares of the firm’s stock in a transaction on Tuesday, January 20th. The shares were bought at an average cost of $19.60 per share, for a total transaction of $353,819.20. Following the completion of the acquisition, the insider directly owned 1,016,658 shares of the company’s stock, valued at approximately $19,926,496.80. This represents a 1.81% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 330,291 shares of company stock valued at $7,478,785 over the last quarter. Corporate insiders own 45.18% of the company’s stock.

Institutional Trading of Surrozen

A number of large investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. raised its stake in Surrozen by 50.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock worth $34,000 after acquiring an additional 500 shares in the last quarter. Persistent Asset Partners Ltd acquired a new stake in shares of Surrozen in the 4th quarter valued at $99,000. Citadel Advisors LLC grew its holdings in shares of Surrozen by 32.8% in the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after purchasing an additional 3,424 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Surrozen in the 4th quarter worth about $247,000. Finally, Geode Capital Management LLC increased its position in shares of Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after purchasing an additional 5,702 shares in the last quarter. 66.57% of the stock is currently owned by institutional investors.

Trending Headlines about Surrozen

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Major shareholder TCG Crossover GP II purchased 106,658 shares on March 24 at an average $24.69, increasing its stake ~16.9% to 736,554 shares — a strong insider-buy signal that can support the stock. SEC Filing
• Positive Sentiment: TCG Crossover also bought 15,223 shares on March 23 at ~$24.90, a smaller follow-on purchase that further signals insider confidence. SEC Filing
• Positive Sentiment: Cantor Fitzgerald reaffirmed an “overweight” rating with a $40 price target — a materially higher valuation that may attract buyers. Benzinga
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and raised its target to $36. Its analyst also issued a FY2030 EPS forecast (-$3.54), notably less negative than the broader consensus, signaling a more optimistic long-term view. TickerReport
• Neutral Sentiment: Short-interest reports for March show zero shorted shares and a 0.0 days-to-cover metric, but the entries include NaN and look inconsistent — treat this as unreliable data rather than a clear market signal.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.